Actelion Ltd.: Pivlaz (Clazosentan) Phase III Study Initiated to Demonstrate Prevention of Vasospasm-Related Morbidity and All-Cause Mortality After Aneurysmal Subarachnoid Hemorrhage

ALLSCHWIL, Switzerland, Nov. 12, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the initiation of the phase III program, CONSCIOUS-2, for the endothelin receptor antagonist Pivlaz(r) (Clazosentan). The study is designed to evaluate the safety and efficacy of Pivlaz(r) in reducing vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage (aSAH). In earlier studies, the use of Pivlaz(r) was associated with up to 65 percent reduction in vasospasm, a contraction of blood vessels in the brain.